Integrin CD11b activation drives anti-tumor innate immunity.



Schmid, Michael C ORCID: 0000-0002-3445-0013, Khan, Samia Q, Kaneda, Megan M, Pathria, Paulina, Shepard, Ryan, Louis, Tiani L, Anand, Sudarshan ORCID: 0000-0002-4969-6884, Woo, Gyunghwi, Leem, Chris, Faridi, M Hafeez
et al (show 8 more authors) (2018) Integrin CD11b activation drives anti-tumor innate immunity. Nature communications, 9 (1). 5379 - ?.

[img] Text
Schmid MC et al. Nature Communication accepted version 2018.pdf - Accepted Version

Download (52MB)

Abstract

Myeloid cells are recruited to damaged tissues where they can resolve infections and tumor growth or stimulate wound healing and tumor progression. Recruitment of these cells is regulated by integrins, a family of adhesion receptors that includes integrin CD11b. Here we report that, unexpectedly, integrin CD11b does not regulate myeloid cell recruitment to tumors but instead controls myeloid cell polarization and tumor growth. CD11b activation promotes pro-inflammatory macrophage polarization by stimulating expression of microRNA Let7a. In contrast, inhibition of CD11b prevents Let7a expression and induces cMyc expression, leading to immune suppressive macrophage polarization, vascular maturation, and accelerated tumor growth. Pharmacological activation of CD11b with a small molecule agonist, Leukadherin 1 (LA1), promotes pro-inflammatory macrophage polarization and suppresses tumor growth in animal models of murine and human cancer. These studies identify CD11b as negative regulator of immune suppression and a target for cancer immune therapy.

Item Type: Article
Uncontrolled Keywords: Macrophages, Animals, Mice, Transgenic, Melanoma, Experimental, Neovascularization, Pathologic, Benzoates, Thiohydantoins, Proto-Oncogene Proteins c-myc, MicroRNAs, CD11b Antigen
Depositing User: Symplectic Admin
Date Deposited: 07 Nov 2018 08:50
Last Modified: 15 Nov 2019 14:10
DOI: 10.1038/s41467-018-07387-4
URI: http://livrepository.liverpool.ac.uk/id/eprint/3028510
Repository Staff Access